Anticarbohydrate antibodies in patients with inflammatory bowel disease. | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 12, Volume 39, Issue 1, April 2018, Page 260-267 PDF (278.55 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2018.16969 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Mohammed Fakhraldeen1; Huseen Saad Mostafa2 | ||||
| 1Lecturer of internal medicine, Faculty of medicine, Mansoura University | ||||
| 2Consultant clinical pathology, King Fahd hospital, Riyadh, Saudi Arabia | ||||
| Abstract | ||||
| Evaluating antilaminaribioside carbohydrate antibodies (ALCA), antimannobioside carbohydrate antibodies (AMCA) and anti-Saccharomyces cerevisiae antibodies (ASCA), in patients with inflammatory bowel disease (IBD). Subjects and methods: 268 serum samples were used; 115 Crohn’s disease (CD), 83 ulcerative colitis, and 70 healthy control samples. All samples were evaluated using enzyme-linked immunosorbent assay for the following four anticarbohydrate antibodies: ACCA, ALCA, AMCA, and ASCA. Results: In patients with Crohn’s disease the prevalence of the anticarbohydrate antibodies was: ASCA 69%, AMCA 32%, ACCA 28% and ALCA 24% with the highest prevalence being for ASCA (P-value<0.0001) while in patients with ulcerative colitis the prevalence was: ACCA 46%, AMCA 35%, ALCA 23% and ASCA 15% with the highest prevalence being for ACCA (P- value<0.001). Conclusion: Anticarbohydrate antibodies are significantly present in patients with IBD. The use of a panel of anticarbohydrate antibodies may provide additional help in distinguishing IBD from non-IBD disease patterns and narrow the range of differential diagnosis in these patients. | ||||
|
Statistics Article View: 193 PDF Download: 321 |
||||
